BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//DataCutoff//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:DataCutoff · $ORKA readouts
X-WR-CALDESC:Clinical-trial primary completion dates from ClinicalTrials.go
 v\, refreshed nightly by DataCutoff. Not investment advice.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07474792-pcd@datacutoff.com
DTSTAMP:20261118T142521Z
DTSTART;VALUE=DATE:20271001
DTEND;VALUE=DATE:20271002
SUMMARY:~ORKA-002 readout (P2) · Oruka Therapeutics\, Inc. $ORKA
DESCRIPTION:Dose Ranging Study of ORKA-002 in Patients With Moderate-to-Sev
 ere Plaque Psoriasis\n\nPrimary completion date: 2027-10 (estimated) — m
 onth only\, shown on the 1st\nPhase 2 · Immuno · Plaque Psoriasis\nEnrol
 lment: 160 · Sites: 40\n\nPrimary completion = last participant's primary
 -endpoint data collected\; topline results usually follow weeks to months 
 later. Sponsor-reported\, often an estimate. Not investment advice.\n\nhtt
 ps://datacutoff.com/radar.html?nct=NCT07474792\nhttps://clinicaltrials.gov
 /study/NCT07474792
URL:https://datacutoff.com/radar.html?nct=NCT07474792
CATEGORIES:Immuno,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
